PHS
SNDX icon

PFM Health Sciences’s Syndax Pharmaceuticals SNDX Stock Holding History

PFM Health Sciences’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.72M Buy
245,021
+2,054
+0.8% +$44.6K 0.52% 60
2025
Q4 		$5.1M Sell
242,967
-13,521
-5% -$236K 0.51% 52
2025
Q3 		$3.95M Buy
+256,488
New +$3.36M 0.3% 56
2025
Q2 		– Sell
-926,424
Closed -$11.4M – 70
2025
Q1 		$11.4M Buy
926,424
+719,553
+348% +$10.1M 0.83% 29
2024
Q4 		$2.73M Sell
206,871
-217,039
-51% -$3.71M 0.17% 67
2024
Q3 		$8.16M Buy
423,910
+36,553
+9% +$755K 0.46% 44
2024
Q2 		$7.95M Sell
387,357
-271,337
-41% -$5.68M 0.39% 50
2024
Q1 		$15.7M Buy
658,694
+63,171
+11% +$1.41M 0.74% 44
2023
Q4 		$12.9M Sell
595,523
-2,119,712
-78% -$32.6M 0.77% 43
2023
Q3 		$39.4M Buy
2,715,235
+542,798
+25% +$10.3M 1.86% 25
2023
Q2 		$45.5M Buy
2,172,437
+225,785
+12% +$4.7M 1.77% 22
2023
Q1 		$41.1M Buy
1,946,652
+132,018
+7% +$3.28M 1.82% 20
2022
Q4 		$46.2M Buy
1,814,634
+525,561
+41% +$12.3M 1.65% 24
2022
Q3 		$31M Buy
1,289,073
+708,305
+122% +$15.9M 1.12% 44
2022
Q2 		$11.2M Sell
580,768
-1,462,609
-72% -$24.4M 0.43% 57
2022
Q1 		$35.5M Sell
2,043,377
-60,135
-3% -$1.01M 1.33% 36
2021
Q4 		$46M Buy
2,103,512
+246,774
+13% +$4.56M 1.57% 28
2021
Q3 		$35.5M Sell
1,856,738
-288,143
-13% -$4.8M 1.04% 41
2021
Q2 		$36.8M Buy
2,144,881
+660,654
+45% +$12.1M 1.15% 33
2021
Q1 		$33.2M Buy
+1,484,227
New +$33.5M 1.01% 39

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

PFM Health Sciences's SNDX Position: Q1 2026 in Review

PFM Health Sciences increased its Syndax Pharmaceuticals (SNDX) stake by 0.85% in Q1 2026, buying an estimated $44.6K and bringing the position to 245,021 shares worth $5.72M. The position accounts for 0.52% of the portfolio, ranked #60.

PFM Health Sciences first reported a position in SNDX in Q1 2021 and has held it in 20 quarters since. The position peaked at $46.2M in Q4 2022. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • PFM Health Sciences held 245,021 shares of Syndax Pharmaceuticals worth $5.72M as of Q1 2026.
  • PFM Health Sciences bought 2,054 Syndax Pharmaceuticals shares in Q1 2026, an estimated $44.6K.
  • Syndax Pharmaceuticals made up 0.52% of PFM Health Sciences's portfolio in Q1 2026, its #60 holding.
  • PFM Health Sciences first reported a position in Syndax Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • PFM Health Sciences's Syndax Pharmaceuticals position peaked at $46.2M in Q4 2022.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.